HIGHLIGHTS
- who: NSCLC and collaborators from the Shenzhen Technology University, China have published the Article: Population pharmacokinetic study of pemetrexed in chinese primary advanced non-small cell lung carcinoma patients, in the Journal: (JOURNAL)
- what: The authors aimed to establish a PPK model of PEM to describe its pharmacokinetic behavior and to determine the physiological and genetic factors that lead to the variability of its exposure in Chinese patients with primary advanced NSCLC, which provided proof-of-concept for pharmacokinetically-guided dosing of PEM for them. This study had been approved by the Ethics Committee of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.